

S2Medical wins procurement for wound healing items in the Västra Götaland region

S2Medical has won a procurement in the Västra Götaland region for products within the Company's wound healing segment. The agreement with the Västra Götaland region will enter into force on 2023-05-17 and last until 2025-05-16, after which it can be extended by a further maximum of two years. The region has not yet announced any estimated quantity. However, information on quantity may be announced at a later date.

S2Medical's wound healing range consists of several different products that facilitate all phases of wound healing and contribute to a significantly improved quality of life for patients and a reduced cost of care.

"The Västra Götaland region is one of Sweden's largest regions, which makes it extra joyful to finally have the opportunity to supply this region with world-class wound healing items. Our hope is that this is just the beginning of a long collaboration to jointly improve the situation for patients suffering from hard-to-heal wounds." Says the company's CEO Petter Sivlér.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-05-2023 16:45 CET.

Contact Details

Petter Sivlér - CEO, S2Medical AB (publ)

Telephone: +46 (0)8-70 000 50 E-mail: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se
E-mail: ca@vatorsec.se

About S2Medical

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084